Skip to main content

Table 4 Secondary outcomes

From: Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial

Secondary outcomes AP Group
(n = 27)
AR1 Group
(n = 28)
AR2 Group
(n = 30)
AR3 Group
(n = 29)
P value
time of anesthesia, min 31.41 ± 9.61 32.46 ± 8.52 33.50 ± 10.33 33.66 ± 9.08 P = 0.794
time of operation, min 29.52 ± 9.71 30.39 ± 8.48 31.43 ± 10.29 31.62 ± 9.02 P = 0.823
time to full alert, min 7.44 ± 2.38 4.75 ± 1.08a 4.63 ± 1.35a 5.31 ± 1.54a P < 0.001
duration of PACU, min 5.37 ± 1.80 4.04 ± 1.48a 3.40 ± 0.72a 3.59 ± 0.87a P < 0.001
type and dose of drugs used for intraoperative anesthesia management
  alfentanil, μg 772.22 ± 151.49 805.36 ± 181.22 788.33 ± 125.33 786.21 ± 136.21 P = 0.877
  remimazolam, mg NA 18.63 ± 3.68 19.75 ± 4.60 20.83 ± 5.33 P = 0.201
  Propofol, mg 221.11 ± 55.91 NA NA NA NA
intraoperative adverse reactions
  body movement 5 (18.5%) 7 (25.0%) 2 (6.6%) 4 (13.8%) P = 0.052
  cough 0 1 (3.6%) 0 0 P = 0.482
  hypotension 24 (88.9%) 8 (28.6%)a 11 (36.7%)a 10 (34.5%)a P < 0.001
  bradycardia 7 (25.9%) 3 (10.7%) 1 (3.3%) 2 (6.9%) P = 0.061
postoperative adverse reactions
  pain 2 (7.4%) 1 (3.5%) 0 1 (3.4%) P = 0.372
  nausea and vomiting 0 1 (3.5%) 0 1 (3.4%) P = 0.735
  1. Note: Data are presented as the mean ± SD and number (percentage)
  2. Abbreviations: AP Alfentanil and propofol, AR1 Alfentanil followed by remimazolam (0.1 mg/kg), AR2 Alfentanil followed by remimazolam (0.15 mg/kg), AR3 Alfentanil followed by remimazolam (0.2 mg/kg), NA Not applicable, PACU Post anesthesia care unit
  3. a P < 0.05 vs. AP group